Cargando…

Current Status of Raf Kinase Inhibitor Protein (RKIP) in Lung Cancer: Behind RTK Signaling

Lung cancer is the most deadly neoplasm with the highest incidence in both genders, with non-small cell lung cancer (NSCLC) being the most frequent subtype. Somatic mutations within the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene are key drivers of NSCLC progression, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Raquel-Cunha, Ana, Cardoso-Carneiro, Diana, Reis, Rui M., Martinho, Olga
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562953/
https://www.ncbi.nlm.nih.gov/pubmed/31083461
http://dx.doi.org/10.3390/cells8050442
_version_ 1783426441123201024
author Raquel-Cunha, Ana
Cardoso-Carneiro, Diana
Reis, Rui M.
Martinho, Olga
author_facet Raquel-Cunha, Ana
Cardoso-Carneiro, Diana
Reis, Rui M.
Martinho, Olga
author_sort Raquel-Cunha, Ana
collection PubMed
description Lung cancer is the most deadly neoplasm with the highest incidence in both genders, with non-small cell lung cancer (NSCLC) being the most frequent subtype. Somatic mutations within the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene are key drivers of NSCLC progression, with EGFR inhibitors being particularly beneficial for patients carrying the so-called “EGFR-sensitizing mutations”. However, patients eventually acquire resistance to these EGFR inhibitors, and a better knowledge of other driven and targetable proteins will allow the design of increasingly accurate drugs against patients’ specific molecular aberrations. Raf kinase inhibitory protein (RKIP) is an important modulator of relevant intracellular signaling pathways, including those controlled by EGFR, such as MAPK. It has been reported that it has metastasis suppressor activity and a prognostic role in several solid tumors, including lung cancer. In the present review, the potential use of RKIP in the clinic as a prognostic biomarker and predictor of therapy response in lung cancer is addressed.
format Online
Article
Text
id pubmed-6562953
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-65629532019-06-17 Current Status of Raf Kinase Inhibitor Protein (RKIP) in Lung Cancer: Behind RTK Signaling Raquel-Cunha, Ana Cardoso-Carneiro, Diana Reis, Rui M. Martinho, Olga Cells Review Lung cancer is the most deadly neoplasm with the highest incidence in both genders, with non-small cell lung cancer (NSCLC) being the most frequent subtype. Somatic mutations within the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene are key drivers of NSCLC progression, with EGFR inhibitors being particularly beneficial for patients carrying the so-called “EGFR-sensitizing mutations”. However, patients eventually acquire resistance to these EGFR inhibitors, and a better knowledge of other driven and targetable proteins will allow the design of increasingly accurate drugs against patients’ specific molecular aberrations. Raf kinase inhibitory protein (RKIP) is an important modulator of relevant intracellular signaling pathways, including those controlled by EGFR, such as MAPK. It has been reported that it has metastasis suppressor activity and a prognostic role in several solid tumors, including lung cancer. In the present review, the potential use of RKIP in the clinic as a prognostic biomarker and predictor of therapy response in lung cancer is addressed. MDPI 2019-05-10 /pmc/articles/PMC6562953/ /pubmed/31083461 http://dx.doi.org/10.3390/cells8050442 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Raquel-Cunha, Ana
Cardoso-Carneiro, Diana
Reis, Rui M.
Martinho, Olga
Current Status of Raf Kinase Inhibitor Protein (RKIP) in Lung Cancer: Behind RTK Signaling
title Current Status of Raf Kinase Inhibitor Protein (RKIP) in Lung Cancer: Behind RTK Signaling
title_full Current Status of Raf Kinase Inhibitor Protein (RKIP) in Lung Cancer: Behind RTK Signaling
title_fullStr Current Status of Raf Kinase Inhibitor Protein (RKIP) in Lung Cancer: Behind RTK Signaling
title_full_unstemmed Current Status of Raf Kinase Inhibitor Protein (RKIP) in Lung Cancer: Behind RTK Signaling
title_short Current Status of Raf Kinase Inhibitor Protein (RKIP) in Lung Cancer: Behind RTK Signaling
title_sort current status of raf kinase inhibitor protein (rkip) in lung cancer: behind rtk signaling
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562953/
https://www.ncbi.nlm.nih.gov/pubmed/31083461
http://dx.doi.org/10.3390/cells8050442
work_keys_str_mv AT raquelcunhaana currentstatusofrafkinaseinhibitorproteinrkipinlungcancerbehindrtksignaling
AT cardosocarneirodiana currentstatusofrafkinaseinhibitorproteinrkipinlungcancerbehindrtksignaling
AT reisruim currentstatusofrafkinaseinhibitorproteinrkipinlungcancerbehindrtksignaling
AT martinhoolga currentstatusofrafkinaseinhibitorproteinrkipinlungcancerbehindrtksignaling